T cell biomarker predicts which CLL patients will respond to CAR T cell therapy

(University of Pennsylvania School of Medicine) Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don't respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news